Concerns raised by two Harvard researchers over new treatment guidelines for heart risk shouldn’t change the method used for determining what patients should get cholesterol-lowering drugs, top U.S. heart doctors said today at the American Heart Association meeting in Dallas.
A new class of cholesterol-lowering medicines from Pfizer Inc. and Amgen Inc. may struggle to meet sales projections, as latest treatment guidelines suggest doctors should prescribe only drugs proven to help the heart.
U.S. regulators won’t require Amgen Inc., Sanofi, Pfizer Inc. and other companies developing the next class of cardiovascular medicines to prove the therapies prevent heart attacks and death before they’re approved.
Millions of Americans going for an annual checkup in 2014 will come away from the doctor’s office with a new prescription to lower their cholesterol, a move cardiologists say will avert heart attacks and strokes.
Cardiologist Eric Topol had just taken a seat on a cross-country flight last June when he received an urgent e-mail from a patient. The 63-year-old man’s heart was racing and he wanted to know what to do about it.
Medtronic Inc.’s CoreValve replaced damaged aortic valves more safely than expected in patients who can’t tolerate traditional open-heart surgery, leading U.S. regulators to say it won’t need an advisory committee review.